TSWM
JNCE

Tyler-Stone Wealth Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Tyler-Stone Wealth Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1K Hold
750
– – ﹤0.01% 855
2022
Q3 		$2K Hold
750
– – ﹤0.01% 775
2022
Q2 		$2K Hold
750
– – ﹤0.01% 785
2022
Q1 		$5K Hold
750
– – ﹤0.01% 683
2021
Q4 		$6K Buy
+750
New +$6.18K ﹤0.01% 688

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tyler-Stone Wealth Management's JNCE Position: Q4 2022 in Review

Tyler-Stone Wealth Management held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q4 2022 at 750 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #855.

Tyler-Stone Wealth Management first reported a position in JNCE in Q4 2021 and has held it in 5 quarters since. The position peaked at $6K in Q4 2021. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • Tyler-Stone Wealth Management held 750 shares of Jounce Therapeutics, Inc. Common Stock worth $1K as of Q4 2022.
  • Tyler-Stone Wealth Management left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q4 2022.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Tyler-Stone Wealth Management's portfolio in Q4 2022, its #855 holding.
  • Tyler-Stone Wealth Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2021 and has held it in 5 quarters since.
  • Tyler-Stone Wealth Management's Jounce Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Tyler-Stone Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.